CYTH logo

Cyclo Therapeutics (CYTH)

Profile

Full Name

Cyclo Therapeutics, Inc.

Ticker Symbol

CYTH

Exchange

NASDAQ

Country

United States

IPO

May 3, 2000

Indexes

Not included

Employees

8

Key Details

Price

$0.72

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$1.08M(-21.76% YoY)

Annual EPS

-$1.23(+32.79% YoY)

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Aug 27, 24 Maxim Group
Hold
Aug 26, 24 Ascendiant Capital
Buy
Aug 23, 24 HC Wainwright & Co.
Neutral
Aug 16, 24 HC Wainwright & Co.
Buy
May 31, 24 HC Wainwright & Co.
Buy
May 1, 24 HC Wainwright & Co.
Buy
Apr 22, 24 Ascendiant Capital
Buy
Sep 27, 23 Maxim Group
Buy
Mar 21, 23 Maxim Group
Hold
Dec 17, 20 Maxim Group
Buy

Institutional Ownership

  • What is the ticker symbol for Cyclo Therapeutics?
  • Does Cyclo Therapeutics pay dividends?
  • What sector is Cyclo Therapeutics in?
  • What industry is Cyclo Therapeutics in?
  • What country is Cyclo Therapeutics based in?
  • When did Cyclo Therapeutics go public?
  • Is Cyclo Therapeutics in the S&P 500?
  • Is Cyclo Therapeutics in the NASDAQ 100?
  • Is Cyclo Therapeutics in the Dow Jones?
  • When was Cyclo Therapeutics's last earnings report?
  • When does Cyclo Therapeutics report earnings?
  • Should I buy Cyclo Therapeutics stock now?

What is the ticker symbol for Cyclo Therapeutics?

The ticker symbol for Cyclo Therapeutics is NASDAQ:CYTH

Does Cyclo Therapeutics pay dividends?

No, Cyclo Therapeutics does not pay dividends

What sector is Cyclo Therapeutics in?

Cyclo Therapeutics is in the Healthcare sector

What industry is Cyclo Therapeutics in?

Cyclo Therapeutics is in the Drug Manufacturers - Specialty & Generic industry

What country is Cyclo Therapeutics based in?

Cyclo Therapeutics is headquartered in United States

When did Cyclo Therapeutics go public?

Cyclo Therapeutics's initial public offering (IPO) was on May 3, 2000

Is Cyclo Therapeutics in the S&P 500?

No, Cyclo Therapeutics is not included in the S&P 500 index

Is Cyclo Therapeutics in the NASDAQ 100?

No, Cyclo Therapeutics is not included in the NASDAQ 100 index

Is Cyclo Therapeutics in the Dow Jones?

No, Cyclo Therapeutics is not included in the Dow Jones index

When was Cyclo Therapeutics's last earnings report?

Cyclo Therapeutics's most recent earnings report was on Apr 1, 2025

When does Cyclo Therapeutics report earnings?

The date for Cyclo Therapeutics's next earnings report has not been announced yet

Should I buy Cyclo Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page